Clinical and economic burden of fractures in patients with renal osteodystrophy

Clinical Nephrology

Volumn 67, Issue 4, 2007, Pages 201-208

  Schumock, G T ^a   Sprague, S M ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Calcimimetics; Chronic kidney disease; Renal osteodystrophy; Secondary hyperpara; Thyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; ANTICOAGULANT AGENT; CALCIDIOL; CALCIMIMETIC AGENT; CALCITONIN; CALCITRIOL; CALCIUM; CINACALCET; COLECALCIFEROL; DOXERCALCIFEROL; ETIDRONIC ACID; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

AGE DISTRIBUTION; ALBRIGHT SYNDROME; ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE BIOPSY; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIP FRACTURE; HIP SURGERY; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; LUNG EMBOLISM; MEDLINE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PELVIS FRACTURE; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; POSTOPERATIVE PERIOD; QUALITY ADJUSTED LIFE YEAR; REHABILITATION CARE; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SIDE EFFECT; SOFT TISSUE CALCIFICATION; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 34247212912     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP67201     Document Type: Review

References (58)

1. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, BeresJord SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000; 1: 396-399.
2. Andress DL. Vitamin D treatment in chronic kidney disease. Semin Dial. 2005 4: 315-321.
3. Ankjaer-Jensen A, Johnell O. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments. Osteoporos Int. 1996; 4: 265-275.
4. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999; 2: 287-293.
5. Bailie GR, Massry SG. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overview. Pharmacotherapy. 2005; 12:1687-1707.
6. Bellantonio S, Fortinsky R, Prestwood K. How well are community-living women treated for osteoporosis after hip fracture? J Am Geriatr Soc. 2001; 9: 1197-1204.
7. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB. Effect of vitamin D on falls: a meta-analysis. JAMA. 2004; 16: 1999-2006.
8. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 8: 2208-2218.
9. Braithwaite RS, Col NF, Wong JB. Estimating hip fractare morbidity, mortality and costs. J Am Geriatr Soc. 2003; 3: 364-370.
10. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, Grimm R, Liu J, Louis T, Manning W, Matas A, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li S, Li S, Roberts T, Snyder J, Solid C, Wang C, Weinhandl E, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Johnson R, Sheets D, Forrest B, Berrini D, Constantini E, Everson S, Frederiek P, Eggers P, Agodoa L. Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2005; 1 (Suppl 1): A5-7.
11. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002; 4: 570-578.
12. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HC1 on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005; 4: 1793-1800.
13. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006; 1: 149-156.
14. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004; 5: 1174-1181.
15. Drueke TB. Calcimimetics versus vitamin D: what are their relative roles? Blood Purif. 2004; 1: 38-43.
16. Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol. 1997; 6: 1215-1217.
17. El-Kaissi S, Pasco JA, Henrv MJ, Panahi S, Nicholson JG, Nicholson GC, Kotowicz MA. Femoral neck geometry and hip fracture risk: the Geelong osteoporosis study. Osteoporos Int. 2005; 10: 1299-1303.
18. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 2: 489-495.
19. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti-thrombotic and Thrombolytic Therapy. Chest. 2004; 3 (Suppl): 338S-400S.
20. Gehlbach SH, Burge RT, Puleo E, Klar J. Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int. 2003; 1: 53-60.
21. Gillespie WJ, Avenell A, Henry DA, O'Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2001; 1: CD000227.
22. Gist Y, Hetzel L. We the People: Aging in the United States, Census 2000 Special Reports, in, U.S. Department of Commerce, Economics and Statistics Administration. 2004 [cited; Available from: http://www.census.gov/prod/2004pubs/censr-19.pdf.
23. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jorduns JG, Josse S, Mevrier A, Lins RL, Fairey IT. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995; 6976: 358-363.
24. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int. 2003; 1: 2-12.
25. Ho LT, Sprague SM. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002; 6: 488-493.
26. Hove LM. Nerve entrapment and reflex sympathetic dystrophy after fractures of the distal radius. Scand J Plast Reconstr Surg Hand Surg. 1995; 1: 53-58.
27. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006; 7: 1358-1366.
28. Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA. Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures. Am J Kidney Dis. 2002; 4: 843-849.
29. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med. 1997; 2A: 20S-25S; discussion 25S-26S.
30. Jonsson B, Christiansen C, Johnell O, Hedbrandt J, Karlsson G. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol. 1996; (Suppl): 30-38; discussion 39-40.
31. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 3: 855-861.
32. Lau KH, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int. 1999; 4: 295-306.
33. Leinau L, Perazella MA. Hip fractures in end-stage renal disease patients: incidence, risk factors, and prevention. Semin Dial. 2006; 1: 75-79.
34. Lindberg JS, Moe SM. Osteoporosis in end-stage renal disease. Semin Nephrol. 1999; 2: 115-122.
35. Llach F, Yudd M. Pathogenic, clinical, and therapeutic aspects of secondary hyperparathyroidism in chronic renal failure. Am J Kidney Dis. 1998; 2 (Suppl 2): S3-12.
36. Lobao R, Carvalho AB, Cuppari L, Ventura R, Lazaretti Castro M, Jorgetti V, Vieira JG, Cendoroglo M, Draibe SA. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol. 2004; 6: 432-439.
37. Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, Sehoeppe W. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 4: 355-362.
38. Mittalhenkle A, Gillen DL, Stehman-Breen CO. Increased risk of mortality associated with hip fracture in the dialysis population. Am J Kidney Dis. 2004; 4: 672-679.
39. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 11: 1945-1953.
40. Mora Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, Kerr DN. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. QJ Med. 1983; 207: 332-348.
41. Morii H, Inoue T, Nishijima T, Tomokuni T, Ishikawa T, Moriya K, Kawai N, Araki H, Horio M, Shigeoka T, Tani K, Yamaguehi T, Kubodera N. Management of calcium and bone abnormalities in hemodialysis patients. Semin Nephrol. 2004; 5: 446-448.
42. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 4 (Suppl 3): S1-201.
43. Naves M, Diaz-Lopez JB, Gomez C, Rodriguez-Rebollar A, Cannata-Andia JB. Determinants of incidence of osteoporotic fractures in the female Spanish population older than 50. Osteoporos Int. 2005; 12: 2013-2017.
44. Negri AL, Barone R, Quiroga MA, Bravo M, Marino A, Fradinger E, Bogado CE, Zanchetta JR. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Perit Dial Int. 2004; 2: 163-168.
45. Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003; 2: 146-151.
46. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005; 4: 638-649.
47. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev. 2002; 4: 560-569.
48. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988; 5: 876-881.
49. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int. 2004; 4: 301-310.
50. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999; 3: 1084-1093.
51. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004; 4: 870-876.
52. Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ. Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int. 2003; 3: 1116-1120.
53. Tejwani NC, Schachter AK, Immerman I, Achan P. Renal osteodystrophy. J Am Acad Orthop Surg. 2006; 5: 303-311.
54. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 4: 1115-1125.
55. Terzibasioglu AM, Akarirmak U, Saridogan M, Tuzun S. Correlation of back pain, compression fracture and quadriceps muscle strength with bone mineral density in renal insufficiency patients. Eura Medicophys. 2005; 4: 303-308.
56. Todd CJ, Freeman CJ, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, Parker MJ, Payne BV, Rushton N. Differences in mortality after fracture of hip: the east Anglian audit. BMJ. 1995; 6984: 904-908.
57. Vautour LM, Melton LJ 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int. 2004; 2: 160-167.
58. Yamamoto M, Yamaguchi T, Sugimoto T. Increased fracture rate in patients with type 2 diabetes mellitus is independent of its bone mineral density. Clin Calcium. 2006; 8: 48-54.